The uncalibrated prothrombinase-induced clotting time test: Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin

Hamostaseologie

Volumn 30, Issue 4, 2010, Pages 212-216

  Korte, Wolfgang ^a,b   Jovic, R ^a   Hollenstein, M ^a   Degiacomi, P ^a   Gautschi, M ^c   Ferrandez A ^c  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c DSM NUTRITIONAL PRODUCTS LTD   (Switzerland)

Author keywords

Anticoagulation monitoring; aPTT; PiCT; Universal functional assay

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; BLOOD CLOTTING TIME; CALIBRATION; HUMAN; PROTEIN EXPRESSION; RELIABILITY; SENSITIVITY ANALYSIS;

EID: 78649987468     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619058     Document Type: Article

References (15)

1. Kher A, Samama MM. Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists. J Thromb Haemost 2005; 3: 473-481.
2. Iorio A. Prevention of venous thromboembolism after major orthopedic surgery: summing up evidence about old and new antithrombotic agents. J Thromb Haemost 2004; 2: 1055-1057.
3. Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood 2005; 105: 453-463.
4. Brill-Edwards P, Ginsberg JS, Johnston M et al. Establishing a therapeutic range for heparin therapy. Annals of internal medicine 1993; 119: 104-109.
5. Harenberg J. Is laboratory monitoring of low-molecular- weight heparin therapy necessary? Yes. J Thromb Haemost 2004; 2: 547-550.
6. Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost 2004; 2: 551-554.
7. Shojania AM. More on: is laboratory monitoring of low-molecular-weight heparin necessary? J Thromb Haemost 2004; 2: 2276-2277.
8. Bachmann F. Laboratory monitoring of low-molecular- weight heparin therapy. J Thromb Haemost 2004; 2: 1005-1006.
9. Kearon C. Laboratory monitoring of low-molecular- weight heparin therapy. J Thromb Haemost 2004; 2: 1006-1007.
10. Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM et al. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. An evaluation of native blood and plasma assays. Thrombosis and haemostasis 1994; 72: 685-692.
11. Rosborough TK. Comparing different lots of activated partial thromboplastin time reagent: analysis of two methods. American journal of clinical pathology 1998; 110: 173-177.
12. Walenga JM, Hoppensteadt DA. Monitoring the new antithrombotic drugs. Seminars in thrombosis and hemostasis 2004; 30: 683-695.
13. Mischke R. Effect of reagent batch on activated partial thromboplastin time in canine plasma and use of the ratio system for standardization. Berliner und Münchener tierärztliche Wochenschrift 2002; 115: 225-229.
14. Girolami A, Vettore S. Discrepancies between clotting and chromogenic assays in congenital coagulation disorders: the hemostatic coin has only one face, chromogenic substrates many. Blood Coagul Fibrinolysis 2009; 20: 484-485.
15. Calatzis A, Peetz D, Haas S et al. Prothrombinaseinduced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular- weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol 2008; 130: 446-454.